[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiol Therapeutics Inc (CRDL.TO)

Cardiol Therapeutics Inc (CRDL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Stocks in play: Cardiol Therapeutics Inc.

Will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference ...

CRDL.TO : 1.82 (+0.55%)
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

TORONTO , May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.82 (+0.55%)
CRDL : 1.3200 (+0.76%)
Stocks in play: Cardiol Therapeutics Inc.

Today announced that the results from its Phase II study evaluating CardiolRxâ„¢ in patients with recurrent ...

CRDL.TO : 1.82 (+0.55%)
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

TORONTO, ON , May 7, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.82 (+0.55%)
CRDL : 1.3200 (+0.76%)
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

TORONTO, ON , May 7, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.82 (+0.55%)
CRDL : 1.3200 (+0.76%)
Stocks in play: Cardiol Therapeutics Inc.

Today announced the continued expansion of its pivotal Phase III MAVERIC trial in the United States, ...

CRDL.TO : 1.82 (+0.55%)
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

TORONTO , April 28, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.82 (+0.55%)
CRDL : 1.3200 (+0.76%)
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

TORONTO , April 28, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory and...

CRDL.TO : 1.82 (+0.55%)
CRDL : 1.3200 (+0.76%)
Upcoming Meeting Dates - April 20, 2026

Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies through...

SGN.VN : 0.335 (-9.46%)
TXP.TO : 0.1350 (unch)
MAI.VN : 6.195 (-0.40%)
WVM.VN : 1.670 (-0.60%)
BRAG.TO : 2.24 (-4.68%)
BRM.VN : 3.340 (-4.30%)
BYRG.CN : 0.2100 (unch)
CPH.TO : 16.76 (-0.71%)
GAME.VN : 1.800 (+5.88%)
RSM.VN : 0.315 (+5.00%)
ESM.TO : 0.1800 (-2.70%)
IPT.VN : 0.330 (-5.71%)
Stocks in play: Cardiol Therapeutics Inc.

Announced that Cardiol's President and Chief Executive Officer David Elsley, will participate in a live ...

CRDL.TO : 1.82 (+0.55%)

Barchart Exclusives

Nvidia Had Another ‘Usual’ Quarter: How to Play NVDA Stock After Q1 Earnings
NVDA stock fell despite stellar fiscal Q1 2027 earnings. Nvidia still looks a buy given continued growth in the AI chip market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.